FRAZIER KENNETH C
SEC CIK 1181175 · EDGAR
BoughtSold
Most active insiders at EIKN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Column Group Opportunity III, LP | 10% | $38.12M | — |
| 2 | Wolfe Josh | Dir, 10% | $5.00M | — |
| 3 | Lux Ventures V, L.P. | 10% | $5.00M | — |
| 4 | FRAZIER KENNETH C | Dir | $2.00M | — |
| 5 | Column Group IV GP, LP | 10% | $1.03M | — |
| 6 | Foresite Capital Opportunity Management V, LLC | 10% | $1000.0K | — |
| 7 | PERLMUTTER ROGER M | See remarks, Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-06 | 2026-02-04 | EIKN | Eikon Therapeutics, Inc. | FRAZIER KENNETH C | Dir | P - Purchase | $18.00 | +111.1K | 111.1K | New | +$2.00M | |
| DM | 2022-11-08 | 2022-11-07 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $99.55 | -235.8K | 785.4K | -23% | -$23.47M |
| D | 2022-11-08 | 2022-11-07 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +235.8K | 936.4K | +34% | $0 |
| DM | 2022-11-07 | 2022-11-03+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $98.66 | -470.0K | 721.0K | -39% | -$46.37M |
| DM | 2022-11-07 | 2022-11-03+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +470.0K | 935.7K | +101% | $0 |
| DM | 2022-11-03 | 2022-11-01+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $99.86 | -600.0K | 707.0K | -46% | -$59.92M |
| DM | 2022-11-03 | 2022-11-01+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +600.0K | 866.5K | +225% | $0 |
| DM | 2022-11-03 | 2022-11-01 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | G - Gift | $0.00 | -5,630 | 700.7K | -0.8% | $0 |
| DM | 2022-11-01 | 2022-10-28+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $100.44 | -867.1K | 935.6K | -48% | -$87.09M |
| DM | 2022-11-01 | 2022-10-28+ | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +867.1K | 1.27M | +213% | $0 |
| 2022-02-28 | 2022-02-24 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | A - Grant | $73.51 | +119.5K | 706.3K | +20% | +$8.78M | |
| D | 2021-11-10 | 2021-11-09 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | M - OptEx | $0.00 | +663.9K | 1.25M | +113% | $0 |
| DM | 2021-11-10 | 2021-11-09 | MRK | Merck & Co. | FRAZIER KENNETH C | Executive COB, Dir | S - Sale+OE | $82.27 | -663.9K | 586.8K | -53% | -$54.61M |
Purchase Sale Sale after option exercise All abbreviations